Literature DB >> 28645356

[Endocrine control of serum phosphate: from the discoveries of phosphatonins to novel therapies].

A Linglart1, C Chaussain2.   

Abstract

Phosphate is absorbed through the gut, stored in the bone and reabsorbed through the proximal renal tubule. More importantly, PTH and FGF23 have been identified as the main phosphaturic factors that control the expression of the phosphate co-transporters NaPi-IIa et IIc. By allowing the adjustment of the urinary phosphate reabsorption, these two phosphatonins play a major role in bone and tooth mineralization and growth. Recently, novel therapies have successfully targeted the FGF23 signaling pathway to treat the hypophosphatemia in patients affected with molecular defects of this pathway (mutations in the PHEX gene).
© 2016 Elsevier Masson SAS. Tous droits réservés.

Entities:  

Keywords:  Dents; FGF23; Hyperphosphatemia; Hyperphosphatémie; Hypophosphatemia; Hypophosphatémies; KLOTHO; Osteocyte; PTH; Teeth; osteocyte

Mesh:

Substances:

Year:  2016        PMID: 28645356     DOI: 10.1016/S0003-4266(17)30076-8

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  1 in total

1.  Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia.

Authors:  Yuan-Yuei Chen; Tung-Wei Kao; Cheng-Wai Chou; Chen-Jung Wu; Hui-Fang Yang; Ching-Huang Lai; Li-Wei Wu; Wei-Liang Chen
Journal:  Sci Rep       Date:  2018-02-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.